1092-04-2

Basic information

• Product Name: Estr-4-en-3-one, 17.beta.-hydroxy-2.alpha.-methyl-
• Synonyms: Estr-4-en-3-one, 17.beta.-hydroxy-2.alpha.-methyl-;17beta-hydroxy-2alpha-methylestr-4-en-3-one
• CAS NO: 1092-04-2
• Molecular Formula: C19H28O2
• Molecular Weight: 0
• Mol File: 1092-04-2.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 439.4°C at 760 mmHg
• Flash Point: 187.3°C
• Appearance: /
• Density: 1.11g/cm³
• Vapor Pressure: 1.44E-09mmHg at 25°C
• Refractive Index: 1.557
• CAS DataBase Reference: Estr-4-en-3-one, 17.beta.-hydroxy-2.alpha.-methyl-(CAS DataBase Reference)
• NIST Chemistry Reference: Estr-4-en-3-one, 17.beta.-hydroxy-2.alpha.-methyl-(1092-04-2)
• EPA Substance Registry System: Estr-4-en-3-one, 17.beta.-hydroxy-2.alpha.-methyl-(1092-04-2)

Safety Data

• Hazardous Substances Data: 1092-04-2(Hazardous Substances Data)

Usage

Definition

ChEBI: A 3-oxo Delta4-steroid that is estr-4-ene substituted by a beta-hydroxy group at position 17 and an alpha-methyl group at position 2.

InChI:InChI=1/C19H28O2/c1-11-9-15-12(10-17(11)20)3-4-14-13(15)7-8-19(2)16(14)5-6-18(19)21/h10-11,13-16,18,21H,3-9H2,1-2H3/t11-,13+,14-,15+,16+,18+,19+/m1/s1

Upstream product

• 434-22-0 19-nortestosterone 
• 1425-10-1 19-nortestosterone acetate 
• 4787-54-6 2-Methyl-oestradiol-3-methylether 
• 3919-20-8 2β-Methyl-17β-hydroxy-oestr-4-en-3-on 
• 74-88-4 methyl iodide 
• 15410-31-8 2-Methoxymethyl-oestradiol-3-methylaether 

Relevant articles and documents

NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF

Provided herein are 19-nor C3, 3-disubstituted steroids of Formula (I) : and pharmaceutically acceptable salts thereof; wherein R1, R2, R3, and R4are as defined herein, and A is a heteroaryl ring system comprising 3 or 4 nitrogens as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and/or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and/or withdrawal syndromes, and tinnitus.

19-NOR C3,3-DISUBSTITUTED C21-N-PYRAZOLYL STEROIDS AND METHODS OF USE THEREOF

Provided herein are 19-nor C3,3-disubstituted C21-pyrazolyl steroids of Formula (I), and pharmaceutically acceptable salts thereof; wherein-, R1, R2, R3a, R3b, R4a, R4b, R5, R6, and R7are as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and/or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and/or withdrawal syndromes, and tinnitus.